News
Phase I/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and glycolipid-packaged nanocells
Phase I/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and glycolipid-packaged nanocells
PASO Joins ClinTrial Refer
ClinTrial Refer is pleased to welcome PASO Medical to the ClinTrial Refer community!
A cancer genius died from cancer. His startup is getting revenge
Sanjiv Gambhir had an ingenious solution to an age-old problem in the fight against cancer. He never said it would be easy.
Precision medicine for cancer patients now more accessible
Thanks to a significant donation from PASO Medical, Monash Health Pathology is now able to sequence chromosomes at a substantially larger scale.
NEW Bladder Cancer Clinical Trial – MK3475-057 Keynote Study
The MK-3475-057 study is a Phase II Clinical Trial for Bladder Cancer. This trial targets patients with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy.
Advanced Solid Tumour Study – Preliminary Efficacy Results Are Promising – ASCO 2019
Advanced Solid Tumour Study – Preliminary Efficacy Results Are Promising – ASCO 2019
Exciting Results For Prostate Cancer Patients
The ENZAMET Trial results were presented at the ASCO Annual Meeting (the world’s largest oncology conference). ENZAMET was one of 4 clinical trials chosen for presentation at the Plenary (Main) Session at the ASCO Conference on 3/6/19 (out of 3500 abstracts).
Going dry this July will help more than just your health!
Melbourne oncologist A/Prof Vinod Ganju explains what you can do to help those living with cancer.
PASO to conduct Odonate study of new anti-cancer drug
Peninsula & Southeast Haematology and Oncology Research Group have commenced the Odonate Therapeutics Inc research study of the new anti-cancer drug, tesetaxel, as a possible treatment for human epidermal growth factor receptor 2 (HER2) negative, hormone receptor (HR) positive breast cancer that is locally advanced or spread to one or more body parts.